The case for & against
Bull & Bear analysis
Bearish
Vivos Therapeutics, Inc. (NASDAQ: VVOS) operates within the healthcare sector, specializing in the innovative treatment of obstructive sleep apnea (OSA) through proprietary oral appliances. Following the strategic acquisition of the Sleep Center of Nevada (SCN), Vivos aims to enhance its service delivery model while capitalizing on the growing demand for alternative OSA treatments. The company is currently transitioning from a dental-centric approach to a comprehensive medical service organization, which positions it well within the evolving sleep medicine market.
Bull says
- ↑Q1 2026 revenue rose 70% YoY to $5.1M, driven by SCN acquisition.
- ↑71% patient acceptance over CPAP indicates robust demand for Vivos.
- ↑Insomnia and pediatric services slated for >60% gross margins.
- ↑Cash‐positive operations expected by Q4 2025 via service expansion.
- ↑Streeterville Capital funding secures liquidity for operational shift.
- ↑Solid liquidity and 2.8% dividend yield support financial stability.
Bear says
- ↓2025 net loss of $21.2M and Q1 2026 operating cash burn of $6M.
- ↓VIP enrollment revenue fell $1.4M, highlighting legacy model decline.
- ↓High short interest and analyst downgrades reflect negative sentiment.
- ↓Scaling SCN integration and provider network carries execution risk.
- ↓Negative profitability and revision factors signal weak earnings outlook.
- ↓Cash reserves of $2.3M necessitate further financing, risking dilution.
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 06-04-2026neutral
Transcript signals
Bull points
- $100,000
- $200,000
- We sold 3,736 oral appliance arches during the first quarter of 2025 for a total of approximately $1.8 million compared to 1,996 during the first quarter of 2024 for $1.7 million. The 8% year-over-year increase in product sales is attributable in part to higher volume in sales of our guides, which are lower revenue generating products compared to our vivos care appliances.
Bear points
- $3 million
- 3.4 million
- Year-over-year decrease was due to lower service revenue, in particular, VIP enrollment revenue, resulting from Vivos' change in our marketing and sales strategy.
Read full transcript analysis ›